Does Alzheimer’s Start in the Heart of the Cholinergic System?
In people with Alzheimer’s biomarkers, the basal forebrain shrinks early, foreshadowing microglial neurotoxicity, atrophy in the medial temporal lobe, and cognitive decline.
204 RESULTS
Sort By:
In people with Alzheimer’s biomarkers, the basal forebrain shrinks early, foreshadowing microglial neurotoxicity, atrophy in the medial temporal lobe, and cognitive decline.
Alector’s AL002c antibody mobilizes microglia, reduces neuronal dystrophy, and restores normal behavior—all in mice. The clinical version is in Phase 1.
The transcription factor NFATc2 mediates this response.
At HAI 2020, scientists more precisely quantified the relationship between plaques, tangles, and cognitive decline.
By engaging scientists studying every tau-based disorder, a new conference aimed to foster collaborations and research directions.
Tau2020: Meeting for Tauopathies Debuts Genetic Variants Behold the First Human α-Synuclein CryoEM Fibril Structure New at Tau2020: PET Detects First Traces of Tangles in Rhinal Cortex Primary Tauopathies Get New PET Ligands Tau Receptor Identified on Cel
Not sure where that is? You are not alone. It is a tiny spot deep behind the nose, newly defined by the PET signal of early neurofibrillary tangle deposition. It also prompted a tau-staging scheme.
Autopsy data confirm that current tau PET tracers are unsuitable for some primary tauopathies. CryoEM structures help researchers find new ligands for tau and α-synuclein.
At Tau2020 conference, scientists implicate LDL receptor-related protein 1 in cell-to-cell transmission.
The monoclonal antibody activated TREM2 signaling on mouse microglia. It supported their survival and stimulated their clearance of amyloid plaques.
A survey conducted by the Alzheimer’s Association finds that three-quarters of these physicians had little to no residency training in dementia care.
United Kingdom’s DRI pivots to fight COVID-19. The facility could test 10,000 samples per day.
From caregivers going it alone to understaffed nursing homes on lockdown, people with neurodegenerative disease and their caregivers are feeling enormous strain from the novel coronavirus. They are adapting to the new normal with technology.
Two papers report that phosphorylated tau in the blood distinguishes people with AD from healthy controls and from people with frontotemporal and vascular dementias.
A trial of nearly 20,000 participants found no benefit over five years.